Sangamo BioSciences Reports Third Quarter 2009 Financi... (e timing of initiation and completion of...)

Sangamo BioSciences Reports Third Quarter 2009 Financial Results

Date:11/4/2009

e timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable ZFP-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SELECTED CONSOLIDATED FINANCIAL DATA
(in thousands, except per share data)
(unaudited)

STATEMENT OF OPERATIONS DATA:

Three Months Ended Nine Months Ended
September 30, September 30,
---------------- ----------------
2009 2008 2009 2008
---- ---- ---- ----

Revenues
Collaboration agreements $4,012 $3,196 $11,382 $7,658
Research grants 51 549 564 1,694
-- --- --- -----
Total revenues 4,063 3,745 11,946 9,352

Operating expenses:
Research and development 6,166 7,563 20,299 24,492
General and administrative 2,701 2,564 8,634 8,036
Total operating expenses 8,867 10,127 28,933 32,528

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
4. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
5. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
6. Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
7. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
8. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
9. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
10. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference

Post Your Comments:

Sangamo BioSciences Reports Third Quarter 2009 Financi...(e timing of initiation and completion of...),Health